Abzena and Mabqi Form Strategic Partnership to Accelerate Antibody Drug Development

Abzena, a leading end-to-end contract development and manufacturing organization (CDMO) for complex biologics and bioconjugates, has announced a strategic partnership with Mabqi, a biotechnology company specializing in fully human antibody discovery. The collaboration aims to provide biopharma customers with a streamlined, integrated solution from antibody discovery through clinical development and manufacturing.

The partnership combines Mabqi’s antibody discovery expertise with Abzena’s development and GMP manufacturing capabilities, bridging the gap between early discovery and pre-clinical development. By integrating their platforms, the companies plan to deliver faster development timelines, enhanced scientific support, and reduced risk for therapeutic antibody programs.

Mabqi’s LiteMab Antibody Discovery Studio will power hit screening, characterization, and lead selection, while Abzena will provide services including developability assessment, cell line development, process development, and GMP manufacturing. Together, the companies can support a broad range of modalities — from monoclonal antibodies and fragments to bi- and multi-specifics and bioconjugates.

“Our partnership with Mabqi brings together two science-rich organizations focused on advancing antibody innovation through integration,” said Campbell Bunce, Chief Scientific Officer at Abzena. “By leveraging data early in development, we can help our customers move more efficiently from discovery to the clinic.”

Sylvain Yon, CEO of Mabqi, added, “This partnership represents a major step toward an integrated antibody discovery-to-development offering. Our complementary expertise and shared commitment to innovation will accelerate the creation of differentiated antibody therapies that can make a real difference for patients worldwide.”

The collaboration underscores both companies’ commitment to driving innovation and efficiency in biologics development by delivering an end-to-end antibody discovery and manufacturing ecosystem for the global biopharma industry.